These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24549600)

  • 41. Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.
    Raaz-Schrauder D; Schrauder MG; Stumpf C; Lewczuk P; Kilian T; Dietel B; Garlichs CD; Schlundt C; Achenbach S; Klinghammer L
    Heart Vessels; 2017 Nov; 32(11):1304-1313. PubMed ID: 28567553
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.
    Kulcsar-Jakab E; Petho Z; Pap Z; Kalina E; Foldesi R; Balogh A; Antal-Szalmas P; Bhattoa HP
    BMC Musculoskelet Disord; 2015 Aug; 16():227. PubMed ID: 26311162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
    Evans CE; Mylchreest S; Andrew JG
    BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
    Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
    Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.
    Pepene CE; Ilie IR; Marian I; Duncea I
    Eur J Endocrinol; 2011 Jan; 164(1):61-8. PubMed ID: 20974706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis.
    Pilichou A; Papassotiriou I; Michalakakou K; Fessatou S; Fandridis E; Papachristou G; Terpos E
    Clin Biochem; 2008 Jun; 41(9):746-9. PubMed ID: 18355453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Osteoprotegerin and nuclear factor-kappaB ligand are associated with leptin and adiponectin levels, in apparently healthy women.
    Tenta R; Panagiotakos DB; Fragopoulou E; Nomikos T; Pitsavos C; Chrysohoou C; Antonopoulou S; Stefanadis C
    J Musculoskelet Neuronal Interact; 2010 Jun; 10(2):174-9. PubMed ID: 20516635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy.
    Miheller P; Muzes G; Rácz K; Blázovits A; Lakatos P; Herszényi L; Tulassay Z
    Inflamm Bowel Dis; 2007 Nov; 13(11):1379-84. PubMed ID: 17663430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
    Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
    Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum osteoprotegerin in adolescent girls with anorexia nervosa.
    Misra M; Soyka LA; Miller KK; Herzog DB; Grinspoon S; De Chen D; Neubauer G; Klibanski A
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3816-22. PubMed ID: 12915674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort.
    Tietze H; Pott V; Kanzelmeyer N; Memaran N; Baumann U; Mindermann C; Suhlrie A; Drube J; Melk A; Das AM; Schnabel D; Haffner D; Leifheit-Nestler M
    Osteoporos Int; 2024 Mar; 35(3):533-542. PubMed ID: 37940696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.
    Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E
    Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.
    LaCroix AZ; Jackson RD; Aragaki A; Kooperberg C; Cauley JA; Chen Z; Leboff MS; Duggan D; Wactawski-Wende J
    Bone; 2013 Oct; 56(2):474-81. PubMed ID: 23735608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration.
    Marini H; Minutoli L; Polito F; Bitto A; Altavilla D; Atteritano M; Gaudio A; Mazzaferro S; Frisina A; Frisina N; Lubrano C; Bonaiuto M; D'Anna R; Cannata ML; Corrado F; Cancellieri F; Faraci M; Marini R; Adamo EB; Wilson S; Squadrito F
    J Bone Miner Res; 2008 May; 23(5):715-20. PubMed ID: 18433304
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women.
    Uemura H; Yasui T; Miyatani Y; Yamada M; Hiyoshi M; Arisawa K; Irahara M
    J Endocrinol Invest; 2008 Feb; 31(2):163-8. PubMed ID: 18362509
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers.
    Herrmann M; Herrmann W
    Clin Chem Lab Med; 2004; 42(12):1384-9. PubMed ID: 15576300
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort.
    Sarink D; Yang J; Johnson T; Chang-Claude J; Overvad K; Olsen A; Tjønneland A; Fournier A; Mancini FR; Kvaskoff M; Boeing H; Trichopoulou A; Karakatsani A; Valanou E; Agnoli C; Sacerdote C; Masala G; Mattiello A; Tumino R; Van Gils CH; Skeie G; Gram IT; Weiderpass E; Lujan-Barroso L; Petrova D; Santiuste C; Quirós JR; Barricarte A; Amiano P; Travis RC; Gunter M; Dossus L; Christakoudi S; Kaaks R; Fortner RT
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1746-1754. PubMed ID: 31292137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A study of relationship between dialectical classification according to traditional Chinese medicine of acute coronary syndrome with serum osteoprotegerin and its ligand].
    Luo ZR; Zheng WX; Huang MF; Chen H; Wang ZQ
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Nov; 25(11):673-6. PubMed ID: 24225213
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism.
    Pepene CE; Crişan N; Coman I
    Clin Invest Med; 2011 Aug; 34(4):E232. PubMed ID: 21810381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.